Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: A partial solution to africa's HIV/AIDS problem?

Carpenter, 1997, Antiviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society: USA Panel, JAMA, 277, 1962, 10.1001/jama.1997.03540480062040 Villani, 1996, Pharmacokinetics of hydroxyurea, in patients infected with human immunodeficiency virus type 1, J Clin Pharmacol, 36, 117, 10.1002/j.1552-4604.1996.tb04176.x Lori, 1994, Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication, Science, 266, 801, 10.1126/science.7973634 Malley, 1994, Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes, 91, 11017 Lori, 1996, Hydroxyurea as an antiviral drug against HIV-1-resistant mutants Gao, 1994, Anti-human immunodeficiency virus-type 1 activity of hydroxyurea, in combination with 2′,3′-dideoxynucleosides, Mol Pharmacol, 46, 767 Malley, 1994, Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds, Lancet, 343, 1292, 10.1016/S0140-6736(94)92182-2 Montaner, 1997, A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080, J Infect Dis, 175, 801, 10.1086/513974 Lori, 1997, Long-term suppression of HIV-1 by hydroxyurea and didanosine, JAMA, 277, 1437, 10.1001/jama.1997.03540420033024 Lori, 1996, Sustained absence of viral rebound consistently observed in patients treated with a combination of hydroxyurea and didanosine Biron, 1995, Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1 infected individuals, J Acquired Immune Defic Syndr Hum Retrovirol, 10, 36, 10.1097/00042560-199509000-00005 Vila, 1996, One-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection, Lancet, 348, 203, 10.1016/S0140-6736(05)66157-0 Ruiz, 1996, Antiviral activity after 24 weeks of the didanosine and hydroxyurea combination in HIV-1-infected patients with CD4+ mean values below 200/mm3 Foli, 1997, Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine, Antiviral Ther, 2, 31 Vila, 1997, Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide, Lancet, 350, 635, 10.1016/S0140-6736(97)24035-3 Lori, 1997, Overcoming drug resistance to HIV-1 by the combination of cell and virus targeting Williams, 1995, A pilot study of the effect of ddl and hydroxyurea on HIV viral burden Lafeuillade, 1995, Hydroxyurea and HIV-1 viraemia, AIDS, 9, 1290, 10.1097/00002030-199511000-00016 Donehower, 1992, An overview of the clinical experience with hydroxyurea, Semin Oncol, 19, 11 Gao, 1993, Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus-type 1, 90, 8925 Gao, 1995, Disparate actions of hydroxyurea, in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus, 92, 8333 Giacca, 1996, Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation, J Infect Dis, 174, 204, 10.1093/infdis/174.1.204 Mendelow, 1997, AIDS, antibodies, and apoptosis, Pathogenesis, 1, 1 Orenstein, 1997, Macrophages as a source of HIV during opportunistic infections, Science, 276, 1857, 10.1126/science.276.5320.1857 Bukrinsky, 1991, Quiescent T lymphocytes as an inducible viral reservoir in HIV1 infection, Science, 254, 423, 10.1126/science.1925601 Emberton, 1993, Massive covert action of helper T lymphocytes and macrophages by HIV during the incubations periods of AIDS, Nature, 362, 359, 10.1038/362359a0 Rutschmann, 1997, A controlled trial of didanosine plus stavudine, plus hydroxyurea or placebo in HIV-infected individuals, Antiviral Ther, 2, 115 Rossero, 1997, Combination therapy with stavudine, didanosine, and hydroxyurea in nucleoside-experienced HIV-1 infected individuals: a preliminary report, Antiviral Ther, 2, 119 Galpin, 1998, Improvements in CD4+ cell diversity during a 7-month trial of hydroxyurea in combination with ddl or ddl and d4T Jessen, 1997, Hydroxyurea, ddl, and a protease inhibitor repress HIV in different compartments and reconstitute immunologic functions Galpin, 1998, Safety, sheltering, and synergy of hydroxyurea with ddI or ddI plus d4T in HIV-infected patients